WO2014066506A3 - 8-thio quinazoline derivatives and 8-thio quinoline derivatives, pharmaceutical compositions thereof and methods for jamm protein inhibition - Google Patents

8-thio quinazoline derivatives and 8-thio quinoline derivatives, pharmaceutical compositions thereof and methods for jamm protein inhibition Download PDF

Info

Publication number
WO2014066506A3
WO2014066506A3 PCT/US2013/066388 US2013066388W WO2014066506A3 WO 2014066506 A3 WO2014066506 A3 WO 2014066506A3 US 2013066388 W US2013066388 W US 2013066388W WO 2014066506 A3 WO2014066506 A3 WO 2014066506A3
Authority
WO
WIPO (PCT)
Prior art keywords
thio
derivatives
jamm
methods
pharmaceutical compositions
Prior art date
Application number
PCT/US2013/066388
Other languages
French (fr)
Other versions
WO2014066506A2 (en
Inventor
Han-Jie Zhou
David Wustrow
Original Assignee
Cleave Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleave Biosciences, Inc. filed Critical Cleave Biosciences, Inc.
Publication of WO2014066506A2 publication Critical patent/WO2014066506A2/en
Publication of WO2014066506A3 publication Critical patent/WO2014066506A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Compounds, pharmaceutical compositions, and methods of using such compounds to treat or prevent diseases or disorders associated with or mediated by JAMM proteins are disclosed.
PCT/US2013/066388 2012-10-23 2013-10-23 Compositions and methods for jamm protein inhibition WO2014066506A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261717378P 2012-10-23 2012-10-23
US61/717,378 2012-10-23

Publications (2)

Publication Number Publication Date
WO2014066506A2 WO2014066506A2 (en) 2014-05-01
WO2014066506A3 true WO2014066506A3 (en) 2014-09-12

Family

ID=49515572

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/066388 WO2014066506A2 (en) 2012-10-23 2013-10-23 Compositions and methods for jamm protein inhibition

Country Status (1)

Country Link
WO (1) WO2014066506A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018116072A1 (en) 2016-12-20 2018-06-28 Pi Industries Ltd. Heterocyclic compounds
JP2022505264A (en) * 2018-10-17 2022-01-14 デューク・ユニヴァーシティ Quinone reductase 2 inhibitor for use as a neuroprotective agent

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003081210A2 (en) * 2002-03-21 2003-10-02 Sunesis Pharmaceuticals, Inc. Identification of kinase inhibitors
WO2008024977A2 (en) * 2006-08-24 2008-02-28 Serenex, Inc. Isoquinoline, quinazoline and phthalazine derivatives
WO2010078154A1 (en) * 2008-12-30 2010-07-08 Canon U.S. Life Sciences, Inc. Unsymmetrical cyanine dyes for high resolution nucleic acid melting analysis
WO2012158435A1 (en) * 2011-05-17 2012-11-22 Han-Jie Zhou Compositions and methods for jamm protein inhibition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4499697A (en) 1996-09-13 1998-04-02 New York University Method for treating parasitic diseases with proteasome inhibitors
US7741432B2 (en) 2005-05-27 2010-06-22 Proteolix, Inc. Substrate for Rpn11 enzymatic activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003081210A2 (en) * 2002-03-21 2003-10-02 Sunesis Pharmaceuticals, Inc. Identification of kinase inhibitors
WO2008024977A2 (en) * 2006-08-24 2008-02-28 Serenex, Inc. Isoquinoline, quinazoline and phthalazine derivatives
WO2010078154A1 (en) * 2008-12-30 2010-07-08 Canon U.S. Life Sciences, Inc. Unsymmetrical cyanine dyes for high resolution nucleic acid melting analysis
WO2012158435A1 (en) * 2011-05-17 2012-11-22 Han-Jie Zhou Compositions and methods for jamm protein inhibition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LUKEVICS E ET AL: "Cytotoxic di(8-quinolyl) disulfides", CHEMISTRY OF HETEROCYCLIC COMPOUNDS, KLUWER ACADEMIC PUBLISHERS-CONSULTANTS BUREAU, NE, vol. 43, no. 5, 1 May 2007 (2007-05-01), pages 629 - 633, XP019525672, ISSN: 1573-8353, DOI: 10.1007/S10593-007-0097-7 *
LUKEVICS E ET AL: "Cytotoxicity of metal 8-quinolinethiolates", CHEMISTRY OF HETEROCYCLIC COMPOUNDS, KLUWER ACADEMIC PUBLISHERS-CONSULTANTS BUREAU, NE, vol. 42, no. 6, 1 June 2006 (2006-06-01), pages 761 - 764, XP019433904, ISSN: 1573-8353, DOI: 10.1007/S10593-006-0158-3 *

Also Published As

Publication number Publication date
WO2014066506A2 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
AU2018236800B2 (en) DNA-PK inhibitors
WO2013012915A8 (en) Heterocyclic compounds and uses thereof
WO2015013635A3 (en) Inhibitors of transcription factors and uses thereof
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
EP3389725A4 (en) Compositions and methods for treatment of central nervous system diseases
WO2012064973A3 (en) Heterocyclic compounds and uses thereof
WO2014031928A3 (en) Heterocyclic modulators of hif activity for treatment of disease
EA024842B9 (en) Compounds as modulators of pi3k protein kinase
MY169987A (en) Selective pi3k delta inhibitors
AU2015237050A8 (en) Quinoline derivatives as SMO inhibitors
WO2014055996A3 (en) Rho kinase inhibitors
WO2015010135A3 (en) Compositions for modulating tau expression
WO2014096965A3 (en) Novel heterocyclic compounds as bromodomain inhibitors
WO2012116237A3 (en) Heterocyclic compounds and uses thereof
MX2014005928A (en) Heterocyclic inhibitors of glutaminase.
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
WO2013163190A8 (en) Dna-pk inhibitors
WO2014031487A8 (en) Bivalent inhibitors of iap proteins and therapeutic methods using the same
WO2013192049A3 (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
WO2014031936A3 (en) Heterocyclic modulators of hif activity for treatment of disease
MX2015016741A (en) Dual selective pi3 delta and gamma kinase inhibitors.
EP3069720A4 (en) Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases
WO2012125981A3 (en) Raf kinase inhibitors
EA201500112A1 (en) 3-SUBSTITUTED DERIVATIVES ESTRA-1,3,5 (10), 16-TETRAENA, METHODS OF THEIR PRODUCTION, PHARMACEUTICAL MEANS, WHICH CONTAIN THEM, AND THEIR USE FOR RECEPTION OF MEDICINES
WO2014058921A3 (en) Substituted pyrimidinyl kinase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13785799

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13785799

Country of ref document: EP

Kind code of ref document: A2